Tokyo, Japan and London, UK, 16 May 2018 – Sosei Group Corporation (“Sosei” or the “Company”; TSE Mothers Index: 4565), the world leader in GPCR medicine design and development, today announced that at the Board of Directors meeting held on 15 May 2018, the Company decided, based on the resolution of the Nomination Committee, to submit the following candidates as new External Directors for approval at the 28th Ordinary General Meeting of Shareholders to be held on 22 June 2018.
To enhance the supervisory function of the Board of Directors, provide experienced oversight of our research and development pipeline, and improve management transparency, with the aim of enhancing our overall corporate governance system.
2. Newly Appointed External Director Candidates
2.1. Name and professional history
2.2. Reasons for Appointment
We expect the three individuals to serve as competent External Directors for the reasons below and provide extensive suggestions concerning all aspects of the Company’s corporate management, based on their considerable experience as senior executives and Directors for large publicly-listed international pharmaceutical companies.
Dr Michael Hayden has had a distinguished career as an academic and researcher in the field of genetic medicine, as well as in the pharmaceutical industry, most notably as President of R&D and Chief Scientific Officer at Teva. The Company believes that he will leverage his extensive experience and specialized knowledge to further strengthen the Company’s oversight of its R&D pipeline and so proposes his appointment as External Director.
Mr Kuniaki Kaga has held several important senior positions at leading chemical and pharmaceutical companies in Japan, including Mitsubishi Chemical and Mitsubishi Tanabe Pharma. The Company believes that he will leverage his extensive experience and specialized knowledge to further strengthen the Company’s overall management system and so proposes his appointment as External Director.
Dr David Roblin gained clinical experience as a physician, and later followed with a distinguished career in the pharmaceutical industry, most notably as SVP and Head of R&D for Pfizer in Europe. The Company believes that he will leverage his extensive experience and specialized knowledge to further strengthen the Company’s oversight of its R&D pipeline and so proposes his appointment as External Director.
3. Current Directors Seeking to be Reappointed